SML2733

RLA8

≥98% (HPLC)

• Sinónimos: 8-[3-Methoxy-5-[(1E)-2-(4-methoxyphenyl)ethenyl]phenoxy]octanoic acid
• Fórmula empírica (notación de Hill): C₂₄H₃₀O₅
• Número CAS: 1891020-45-3
• Peso molecular: 398.49
• UNSPSC Code: 12352200
• NACRES: NA.77
• Assay: ≥98% (HPLC)
• Form: powder
• Storage condition: protect from light

Propiedades

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• storage condition: protect from light
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: 2-8°C
• SMILES string: O(CCCCCCCC(=O)O)c1cc(cc(c1)\C=C\c2ccc(cc2)OC)OC
• InChI: 1S/C24H30O5/c1-27-21-13-11-19(12-14-21)9-10-20-16-22(28-2)18-23(17-20)29-15-7-5-3-4-6-8-24(25)26/h9-14,16-18H,3-8,15H2,1-2H3,(H,25,26)/b10-9+
• InChI key: MNKZDYGBWDHRMX-MDZDMXLPSA-N

Descripción

Biochem/physiol Actions

RLA8 is an orally available and potent agonist of peroxisome proliferator-activated receptors (PPARs)-α/γ/δ and G-protein-coupled receptor 40 (GPR40). RLA8 reverses the proregression of pathological changes such as hepatic lipid accumulation, steatosis, inflammation and fibrosis in mice models of nonalcoholic steatohepatitis (NASH). Also, it improves serum HDL cholesterol, reduce hepatic free fatty acid and triglyceride levels, and alleviate insulin resistance.

orally available and potent agonist for PPARs-α/γ/δ and GPR40 that exhibits efficacy to reverse nonalcoholic steatohepatitis and fibrosis

Información de seguridad

• Clase de almacenamiento: 11 - Combustible Solids
• Punto de inflamación (°F): Not applicable
• Punto de inflamación (°C): Not applicable